Non-Hormonal Treatment for Vasomotor Symptoms of Menopause

A Phase III trial evaluating the efficacy and safety of a non-hormonal oral agent for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

Duration

52 weeks

Visits

11 visits

Compensation

Up to $1,100

Study Overview

This randomized, double-blind, placebo-controlled Phase III study evaluates a non-hormonal NK3 receptor antagonist for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) in postmenopausal women. Participants receive once-daily oral treatment for 52 weeks. Primary endpoint is change from baseline in mean daily moderate-to-severe hot flash frequency at Week 12.

Eligibility Criteria

You May Qualify If:

Women aged 40–65 who are postmenopausal
≥7 moderate-to-severe hot flashes per day at baseline
Not using hormone replacement therapy
BMI 18.5–40 kg/m²

You May Not Qualify If:

History of breast, uterine, or ovarian cancer
Uncontrolled hypertension
Use of hormonal therapies within 8 weeks
Significant liver disease

Study Locations

Tampa Main OfficeClearwater Office

Apply for This Study

Complete this brief form and our team will contact you within 1 business day.

Questions? Call us directly:

(813) 815-7327

Back to All Studies